Press Releases

Year None20242023

November 05, 2024

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 01, 2024

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

October 07, 2024

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

September 23, 2024

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

September 22, 2024

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

September 14, 2024

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

August 06, 2024

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

June 01, 2024

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29, 2024

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 09, 2024

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Displaying 1 - 10 of 18